2023
Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims
Huntington S, Chang H, Fu A, Loefgren C, Lu X. Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims. Blood 2023, 142: 2348. DOI: 10.1182/blood-2023-181909.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationHealthcare resource utilizationAcute myeloid leukemia patientsRetrospective cohort studyIndex dateMyeloid leukemia patientsAML patientsAML diagnosisR patientsDiagnosis codesEconomic burdenPPPM costsCohort studyContinuous enrollmentND patientsLeukemia patientsMedical costsLarge US administrative claims databaseRefractory acute myeloid leukemia patientsHigher healthcare resource utilizationUS administrative claims databaseMore outpatient encountersNon-HSCT patientsNon-transplant recipientsOlder AML patients
2016
ME2 Medicare Part D Cost Sharing And Specialty Drug Initiation In Newly Diagnosed Chronic Myeloid Leukemia Patients
Doshi J, Li P, Huo H, Pettit A, Kumar R, Huntington S, Weiss B. ME2 Medicare Part D Cost Sharing And Specialty Drug Initiation In Newly Diagnosed Chronic Myeloid Leukemia Patients. Value In Health 2016, 19: a3. DOI: 10.1016/j.jval.2016.03.035.Peer-Reviewed Original Research